Oncology and Cancer Immunology Research Oncology and Cancer Immunology Research Find out more about our research and development in oncology and cancer immunology.
Plasmid DNA Production | BioXcellence Plasmid DNA Production | BioXcellence Discover our range of plasmid DNA production solutions from research to GMP.
global-top-employer global-top-employer For the first time, Boehringer Ingelheim receives the award as a Global Top Employer as well as individual awards in 27 countries.
reduced-heart-failure-treatment-approval-europe reduced-heart-failure-treatment-approval-europe European approval for treatment of adults with heart failure with reduced ejection fraction
Official partner to Cat Care for Life Official partner to Cat Care for Life Boehringer Ingelheim announces its new partnership with the CatCareforLife program.
Perceived burden of COPD is higher for younger patients Perceived burden of COPD is higher for younger patients New global survey reveals perceived burden of disease is greater in younger people living with COPD
Quality Quality At Boehringer Ingelheim, Quality is deeply embedded into the lifecycle of the product: from Research and development to the delivery to our patients.
Immunology Immunology We are looking for new early-science collaborations and invite you to join our expanding community of innovation partners in immunology.
Oncology Oncology We are looking for new early-science collaborations and invite you to join our expanding community of innovation partners in oncology.
Respiratory Diseases Respiratory Diseases We are looking for new early-science collaborations and invite you to join our expanding community of innovation partners in respiratory diseases.
Technologies Technologies We are expanding our global network of technology partners Learn more about partnering with us.
Cardiometabolic Diseases Cardiometabolic Diseases We are looking for new early-science collaborations and invite you to join our expanding community of innovation partners in CardioMetabolic diseases.
EASi-KIDNEY™ Phase III trial for people with CKD EASi-KIDNEY™ Phase III trial for people with CKD Boehringer Ingelheim's Sandy Sommer on how treatment innovations in CKD can also improve care for connected conditions, including heart failure.
Zongertinib (BI 1810631): HER2 Tyrosine Kinase Inhibitor (TKI) | NSCLC Zongertinib (BI 1810631): HER2 Tyrosine Kinase Inhibitor (TKI) | NSCLC Zongertinib (BI 1810631): HER2 Tyrosine Kinase Inhibitor (TKI) | NSCLC
Five ways to include more diversity in clinical trials Five ways to include more diversity in clinical trials
Animal Health Partnering Interests Infectious Diseases May 2024 CORP Animal Health Partnering Interests Infectious Diseases May 2024 CORP
Animal Health Partnering Interests Pain & Mobility May 2024 CORP Animal Health Partnering Interests Pain & Mobility May 2024 CORP
Animal Health Partnering Interests Immunology & Inflammation May 2024 CORP Animal Health Partnering Interests Immunology & Inflammation May 2024 CORP
2024 MORE GREEN infographic - Environmental Stewardship at Boehringer Ingelheim 2024 MORE GREEN infographic - Environmental Stewardship at Boehringer Ingelheim